Artemis Investment Management LLP Raises Position in IQVIA Holdings Inc. $IQV

Artemis Investment Management LLP increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 156.9% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 297,972 shares of the medical research company’s stock after purchasing an additional 181,979 shares during the period. Artemis Investment Management LLP’s holdings in IQVIA were worth $80,110,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of IQVIA in the second quarter worth about $2,811,292,000. Victory Capital Management Inc. increased its position in IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in IQVIA in the 2nd quarter valued at approximately $240,911,000. Bank of America Corp DE bought a new position in IQVIA in the 2nd quarter valued at approximately $235,551,000. Finally, Legal & General Group Plc bought a new stake in shares of IQVIA during the second quarter worth $211,342,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Mizuho boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday. Stifel Nicolaus lifted their price objective on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Barclays increased their target price on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday. HSBC restated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Finally, Robert W. Baird increased their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $274.31.

IQVIA Trading Down 1.1%

IQV stock traded down $2.74 during mid-day trading on Thursday, reaching $255.37. The company’s stock had a trading volume of 297,450 shares, compared to its average volume of 1,713,708. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $277.40. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business’s 50 day moving average price is $256.74 and its 200 day moving average price is $208.40. The company has a market cap of $42.03 billion, a price-to-earnings ratio of 31.71, a price-to-earnings-growth ratio of 2.22 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the firm posted $2.81 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.